17:25 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Digital therapeutics company Pear closes $64M series C round

Pear Therapeutics Inc. (Boston, Mass.) raised $64 million in a series C round to support commercialization of its reSET digital therapeutic portfolio and fund its clinical pipeline. In November, Pear and partner Sandoz Ltd. launched...
22:26 , Jan 4, 2019 |  BC Extra  |  Financial News

Digital therapeutics company Pear closes $64M series C round

Pear Therapeutics Inc. (Boston, Mass.) raised $64 million in a series C round to support commercialization of its reSET digital therapeutic portfolio and fund its clinical pipeline. In November, Pear and partner Sandoz Ltd. launched...
19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
22:05 , Jan 3, 2019 |  BC Extra  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Thursday....
19:53 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Entrada raises $59M series A to take intracellular biologic into clinic

Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Dec. 18 after raising $59 million in a series A round intended to propel its first intracellular biologics program into clinic. Intracellular targets have proven challenging for...
23:03 , Dec 19, 2018 |  BioCentury  |  Finance

MPM goes intracellular

MPM Capital picked Entrada Therapeutics Inc. for its debut investment in intracellular biologics because Entrada’s technology solves the long-time challenge of delivering biologics into cells and shows early promise of broad tissue distribution, MPM Capital’s...
13:00 , Dec 18, 2018 |  BC Extra  |  Financial News

Entrada raises $59M series A to take intracellular biologic into clinic

Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Tuesday after raising $59 million in a series A round intended to propel its first intracellular biologics program into clinic. Intracellular targets have proven challenging for small...
19:01 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners. Existing investors 5AM Ventures,...
18:14 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round on Nov. 30, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic...
11:45 , Dec 6, 2018 |  BC Extra  |  Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners. Existing investors 5AM Ventures,...